John Witbeck, MD
Family Medicine · Salt Lake City, UTNPI 1972522316
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,927 of the $4,704 with a category attached, or 83.5%. 38 manufacturers reported payments, led by Merck at 24.3% of the total. Reporting peaked in 2020 at $1,147 and has fallen 56.3% since, to $501 in 2025.
Across 211 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- AbbVie$929
- GSK$346
- Boehringer Ingelheim$344
- Lilly USA, LLC$240
- Abbott$208
- plus $1K from 32 others
Across 155 payments — averaging $1487.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$231K
What the payments were for
- Travel & lodging$77817%
- Food & beverage$3,92783%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 17 | $1,144 |
| AbbVie | 42 | $929 |
| GSK | 21 | $346 |
| Boehringer Ingelheim | 18 | $344 |
| Lilly USA, LLC | 15 | $240 |
| Abbott | 10 | $208 |
| Phathom Pharmaceuticals, Inc. | 4 | $190 |
| Dynavax Technologies Corporation | 9 | $125 |
| Amgen(2 entities) | 8 | $120 |
| Gilead | 6 | $113 |
| Pfizer | 6 | $88 |
| Novo Nordisk | 5 | $72 |
| Bayer | 4 | $63 |
| AstraZeneca | 5 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $57 |
| Corium, LLC | 3 | $51 |
| Johnson & Johnson | 3 | $49 |
| Biohaven Pharmaceuticals, Inc. | 3 | $47 |
| Quidel Corporation | 1 | $41 |
| Astellas Pharma US Inc | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Corcept Therapeutics | 2 | $30 |
| Seqirus USA Inc | 2 | $30 |
| Genentech USA, Inc. | 2 | $29 |
| Hologic Sales And Service, LLC | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Nevro Corp. | 1 | $21 |
| Radius Health, Inc. | 1 | $20 |
| Boston Scientific | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
| Novartis | 1 | $14 |
| Cranial Technologies, Inc | 1 | $13 |
| Organon | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GARDASIL 9$708
- VOQUEZNA$105
How this compares
$4,704 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 36 | $47,409 |
| FarxigaDapagliflozin Propanediol | 29 | $33,267 |
| XareltoRivaroxaban | 13 | $8,844 |
| Rosuvastatin Calcium | 161 | $2,408 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 16 | $1,267 |
| Levothyroxine Sodium | 119 | $1,211 |
| Losartan Potassium | 105 | $1,128 |
| Omeprazole | 63 | $970 |
| Amlodipine Besylate | 128 | $872 |
| Metformin Hcl | 80 | $777 |
| Atorvastatin Calcium | 98 | $721 |
| Bupropion XlBupropion Hcl | 17 | $653 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $639 |
| Gabapentin | 30 | $633 |
| Testosterone | 16 | $596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $240 | $47,40936 claims |
| AstraZenecaFarxiga | $61 | $33,26729 claims |
| Johnson & JohnsonXarelto | $49 | $8,84413 claims |
| PfizerPaxlovid | $88 | $016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.
Other family medicine in Salt Lake City
- Mark CacciamaniSalt Lake City$43K
- Kirk OdonnellSalt Lake City$23K
- Jared ProbstSalt Lake City$15K
- Derek MuseSalt Lake City$14K
- Kristen RomoSalt Lake City$13K
- Julie DaySalt Lake City$11K
- Mark JohnsonSalt Lake City$8K
- Stephen ColemanSalt Lake City$8K
- David LarsenSalt Lake City$8K
- Michael CobbleSandy$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.